Evidence mapPaperPMID 22019747Full record

ArticleMinerva endocrinologica2011

Adiponectin and E-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease(s).

H O El-Mesallamy, N M Hamdy, T M Salman, S Mahmoud

Registry-linked trialAbstract read
PubMed
In one paragraph

Article in Minerva endocrinologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03693560 (The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03693560 phase4completedstarted 2018, after this paper: background citation

The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases

Ran2018Enrolled80Registered outcomes7Posted comparisons0ConditionsCoronary Artery Disease, Diabetes Mellitus, Type 2ArmsGlimepiride upto 4 mg Oral Tablet, Metformin 1000 mg Oral Tablet, Vildagliptin 50 mg Oral Tablet
Open the trial in the graph
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

H O El-MesallamyBiochemistry Department, Ain Shams University, Cairo, Egypt.
N M Hamdy
T M Salman
S Mahmoud
Ain Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAdipose tissue is now regarded as a source of proinflammatory mediators which may contribute to vascular injury, insulin resistance (IR), and atherogenesis, however, some of them have a protective role against vascular inflammation and/or IR; namely adiponectin and nitric oxide (NO). Adiponectin is a fat derived hormone, which enhances insulin sensitivity. In experimental studies adiponectin was shown to have anti-atherogenic properties by suppressing endothelial expression of adhesion molecules as endothelial-selectin (E-selectin) and inflammatory cytokines as high-sensitivity C-reactive protein (hsCRP), interleukin-1β (IL-1β), and monocyte chemotactic protein-1 (MCP-1). Therefore, the aim of the study was to evaluate plasma adiponectin, E-selectin, hsCRP, IL-1β, and MCP-1 concentrations in obese patients with and without coronary heart disease (CHD) having type 2 diabetes mellitus (DM) and evaluation of their relationship with selected anthropometric, biochemical, and clinical parameters.

methodsThe study group consisted of (N.=70) males, 20 of which served as healthy non-obese controls (group I) (mean age 38.5±3.7 years; mean BMI 28±1.2 kg/m2). Patients enrolled in the study were classified into the following groups: type 2 DM obese subjects without CHD (group II) (N.=25) (mean age 42.2±3 years; mean BMI 32.1±1.4 kg/m2) and type 2 DM obese subjects with CHD (group III) (N.=25) (mean age 40.6±3 years; mean BMI 31.5±1.2 kg/m2). Glucose and insulin estimation was performed and insulin resistance index (HOMA-IR) was calculated. In the fasting state, the plasma HbA1c, adiponectin, E-selectin, in comparison to hsCRP, IL-1β, MCP-1, and lipid parameters were estimated.

resultsFBG, HbA 1c %, lipids, insulin, MDA, NO, hsCRP, IL-?, MCP-1, Adiponectin as well as E-selectin concentration were significantly different in patients with type 2 DM and CHD in comparison to patients without CHD and moreover, the healthy control group (P=0.01). There was a significant negative correlation between adiponectin and E-selectin (r=-0.642; P=0.0001).

conclusionOur study supports the hypothesis that decreased level of adipokine(s), together with increased oxidative stress, pro-inflammatory marker(s) as well as endothelial adhesion molecule(s) contributes to the complex process of atherosclerosis in type 2 diabetic obese patients that may lead eventually to CHD.

Indexed as

AdiponectinAdultAlgorithmsBiomarkersBody Mass IndexCase-Control StudiesChemokine CCL2Coronary DiseaseC-Reactive ProteinDiabetes Mellitus, Type 2E-SelectinGlucose IntoleranceHumansInflammationInsulin ResistanceInterleukin-1betaAdiponectinBiomarkersChemokine CCL2C-Reactive ProteinE-SelectinInterleukin-1beta

Identifiers

PMID22019747
OpenAlexW1457270803

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.